ClearPoint Neuro, Inc. (CLPT) vs Larimar Therapeutics, Inc. (LRMR)
A side-by-side comparison of ClearPoint Neuro, Inc. and Larimar Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CLPT
ClearPoint Neuro, Inc.
$10.90HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
LRMR
Larimar Therapeutics, Inc.
$2.80HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
Total return — CLPT vs LRMR
growth of $100 · dividends reinvested · last 10yCLPT +88.9% (+6.6%/yr)LRMR -92.8% (-23.1%/yr)CLPT compounded faster over this window
Log scale — wide-divergence pair
CLPT LRMR
CLPT vs LRMR: by the numbers
- •CLPT is the larger company ($327M vs $290M market cap).
- •Both run net losses; LRMR's is the smaller (0.00% vs -81.76% net margin).
Metrics side by side
Valuation
| Metric | CLPT | LRMR |
|---|---|---|
| P/S ratio | 7.73 | N/A |
| P/B ratio | 30.33 | 2.28 |
Profitability
| Metric | CLPT | LRMR |
|---|---|---|
| Gross margin | 62.61% | 0.00% |
| Operating margin | -65.36% | 0.00% |
| Net margin | -81.76% | 0.00% |
| ROE | -320.77% | -135.50% |
| ROIC | -40.51% | -136.49% |
Growth (annualized)
| Metric | CLPT | LRMR |
|---|---|---|
| Revenue CAGR (5Y) | 23.57% | N/A |
| Total return CAGR (5Y) | -7.65% | -23.91% |
Frequently asked
- How have CLPT and LRMR total returns compared?
- Over the past 10 years, CLPT delivered 6.57% and LRMR delivered -23.59% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
ClearPoint Neuro ROELarimar Therapeutics ROEClearPoint Neuro operating marginLarimar Therapeutics operating marginClearPoint Neuro revenue growthLarimar Therapeutics revenue growthClearPoint Neuro free cash flowLarimar Therapeutics free cash flow
ClearPoint Neuro & Larimar Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.